Association between regional deprivation and type 2 diabetes incidence in Germany.
incidence
regional deprivation
social inequalities
type 2 diabetes
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
08
2019
revised:
12
11
2019
accepted:
22
11
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
12
9
2020
Statut:
epublish
Résumé
The aim of this analysis was to estimate the association between regional deprivation and type 2 diabetes incidence and to investigate differences by age and sex for Germany. Type 2 diabetes incidence rate ratios comparing the most deprived fifth of the population to the remainder of the population (divided into quintiles) were estimated using the illness-death model, which describes the relationship between prevalence, mortality, and incidence. For the analysis, we used the type 2 diabetes prevalence and the general mortality rate according to deprivation quintiles, which we calculated based on valid estimates for Germany. Because mortality rate ratios for people with type 2 diabetes compared with people without type 2 diabetes are lacking for Germany, we used estimates from Scotland. Estimates were standardized to the German population in 2012 and stratified by sex. Incidence of type 2 diabetes was estimated to be over twice as high among people living in the most deprived regions of Germany compared with people living in the least deprived regions (men: 2.41, 95% CI 1.27 to 4.28; women: 2.40, 95% CI 1.25 to 4.29). The strength of the association increased with increasing age until the age of 75 years. No sex differences were present. The study adds new evidence regarding the association between type 2 diabetes incidence and regional deprivation for Germany. The results underpin the importance to intensify public health actions to reduce social inequalities in Germany and whole Europe in the future.
Identifiants
pubmed: 31908802
doi: 10.1136/bmjdrc-2019-000857
pii: bmjdrc-2019-000857
pmc: PMC6936410
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e000857Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: WR reported receiving consulting fees for attending educational sessions or advisory boards from AstraZeneca, Boehringer Ingelheim and Novo Nordisk and institutional research grants from Novo Nordisk.
Références
Diabetes Care. 2012 Jul;35(7):1455-61
pubmed: 22619081
J Epidemiol Community Health. 2011 Jul;65(7):606-12
pubmed: 20693490
Math Med Biol. 2015 Dec;32(4):425-35
pubmed: 25576933
J Health Monit. 2019 Jun 27;4(2):11-28
pubmed: 35146245
Soc Sci Med. 2007 Nov;65(9):1953-64
pubmed: 17719709
Lancet Diabetes Endocrinol. 2016 Jun;4(6):517-24
pubmed: 27131930
Lancet. 2018 Jun 16;391(10138):2430-2440
pubmed: 29784146
Int J Epidemiol. 2011 Jun;40(3):804-18
pubmed: 21335614
Diabetes Care. 2011 May;34(5):1127-32
pubmed: 21421800
Health Place. 2019 Jul;58:102149
pubmed: 31220800
PLoS One. 2014 Feb 27;9(2):e89661
pubmed: 24586945
J Gerontol B Psychol Sci Soc Sci. 2006 Nov;61(6):S290-8
pubmed: 17114308
BMC Public Health. 2014 Dec 13;14:1264
pubmed: 25495106
J Epidemiol Community Health. 2014 Nov;68(11):1088-95
pubmed: 25073594
Gesundheitswesen. 2012 Jul;74(7):416-25
pubmed: 22020751
Diabet Med. 2013 Mar;30(3):e78-86
pubmed: 23127142
Diabetes Obes Metab. 2017 Nov;19(11):1537-1545
pubmed: 28387052
Sci Rep. 2016 Apr 22;6:24780
pubmed: 27101929
Lancet Public Health. 2018 Aug;3(8):e365-e373
pubmed: 30030110
J Health Monit. 2017 Jun 14;2(2):98-114
pubmed: 37152089
BMJ Open. 2018 Oct 4;8(9):e021143
pubmed: 30287604
IARC Sci Publ. 1980;(32):5-338
pubmed: 7216345
Diabetologia. 2016 Oct;59(10):2106-13
pubmed: 27465219
Health Place. 2013 Sep;23:63-9
pubmed: 23771166